8-K: Centessa Pharmaceuticals Receives FDA Clearance for Phase 1 Trial of Narcolepsy Drug ORX750

Centessa Pharmaceuticals has received FDA clearance to begin a Phase 1 clinical trial for ORX750, a potential treatment for narcolepsy.

Summary

• Centessa Pharmaceuticals announced that the FDA has cleared their Investigational New Drug application for ORX750, allowing them to begin a Phase 1 clinical trial.
• ORX750 is an orally administered orexin receptor 2 agonist being developed for narcolepsy and other sleep-wake disorders.
• The Phase 1 trial will assess the safety, tolerability, and pharmacokinetics of ORX750 in healthy adults using single and multiple ascending doses.
• A proof-of-concept study will also be conducted using the Maintenance of Wakefulness Test and Karolinska Sleepiness Scale in sleep-deprived subjects.
• The company expects to start dosing in the Phase 1 study imminently and anticipates proof-of-concept data in the second half of 2024.
• The study has a maximum exposure limit set by the FDA, but the company believes this limit is significantly higher than the predicted effective dose and will not impact development.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA clearance and the advancement of a promising drug candidate. The company is moving forward with its clinical development plans as expected, and the preclinical data is encouraging. However, there are inherent risks in drug development, which temper the overall sentiment.

Positives

• The FDA clearance of the IND application is a significant step forward for the development of ORX750.
• ORX750 has shown high potency and selectivity for the OX2R receptor, which is crucial for treating narcolepsy.
• Preclinical studies have demonstrated promising results, including increased wakefulness and suppressed cataplexy.
• The company expects to obtain proof-of-concept data in the second half of 2024, which could accelerate further development.
• The study design includes a proof-of-concept component to assess the drug's pharmacodynamic effects early in the trial.

Risks

• The company's ability to successfully conduct clinical trials and obtain regulatory approvals is subject to risks and uncertainties.
• There is a risk that the results of preclinical studies may not be predictive of future results in clinical trials.
• The company's ability to obtain adequate financing to fund its clinical trials is a risk.
• The safety and tolerability profile of ORX750 in humans is still being evaluated in the Phase 1 trial.
• There are general business, regulatory, economic, and competitive risks associated with developing pharmaceutical products.

Future Outlook

The company anticipates commencing dosing in the Phase 1 study imminently and expects to obtain proof-of-concept data in the second half of 2024. They plan to use this data to enable dose selection for future studies in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

Management Comments

• Saurabh Saha, MD PhD, Chief Executive Officer of Centessa, stated that this is a significant milestone for the development of ORX750.
• The CEO also mentioned that they are excited to begin executing what they believe is an elegant, adaptive Phase 1 study aimed at generating early proof-of-concept data.

Industry Context

This announcement is significant in the context of the growing need for effective treatments for narcolepsy and other sleep-wake disorders. The development of a potent and selective orexin agonist like ORX750 could provide a new treatment option for patients suffering from these conditions. Several companies are developing treatments for narcolepsy, but Centessa's approach with ORX750 is unique due to its high selectivity for the OX2R receptor.

Comparison to Industry Standards

• Other companies such as Harmony Biosciences and Jazz Pharmaceuticals have approved treatments for narcolepsy, but these often have different mechanisms of action.
• Harmony Biosciences' Wakix (pitolisant) is a histamine H3 receptor antagonist/inverse agonist, while Jazz Pharmaceuticals' Xyrem (sodium oxybate) is a central nervous system depressant.
• ORX750, as an orexin receptor agonist, directly targets the underlying pathophysiology of orexin neuron loss in narcolepsy type 1, which is a different approach than existing treatments.
• The high selectivity of ORX750 for the OX2R receptor is a key differentiator compared to other orexin agonists in development, potentially leading to fewer side effects.
• The company's focus on a proof-of-concept study in acutely sleep-deprived healthy volunteers is a common approach in early-stage drug development to assess pharmacodynamic effects.

Stakeholder Impact

• Shareholders will likely view the FDA clearance positively, as it represents a significant milestone in the development of ORX750.
• Patients with narcolepsy and other sleep-wake disorders may benefit from the development of a new treatment option.
• Employees of Centessa will be involved in the execution of the Phase 1 trial and the further development of ORX750.
• The company's success in developing ORX750 could lead to increased revenue and growth.

Next Steps

• The company will commence dosing in the Phase 1 study imminently.
• The company expects to obtain proof-of-concept data in the second half of 2024.
• The company will use the Phase 1 data to enable dose selection for future studies in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

Key Dates

Keywords

ORX750, narcolepsy, orexin agonist, Phase 1 trial, FDA, sleep-wake disorders, clinical trial, pharmacokinetics, pharmacodynamics, OX2R agonist